IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2+ Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831.
about
IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2+ Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
IGF1R Protein Expression Is No ...... uvant Trastuzumab Trial N9831.
@en
type
label
IGF1R Protein Expression Is No ...... uvant Trastuzumab Trial N9831.
@en
prefLabel
IGF1R Protein Expression Is No ...... uvant Trastuzumab Trial N9831.
@en
P2093
P2860
P1476
IGF1R Protein Expression Is No ...... juvant Trastuzumab Trial N9831
@en
P2093
Ann E McCullough
Beiyun Chen
Darren Riehle
Edith A Perez
Karla Ballman
Kathleen Tenner
Monica M Reinholz
Robert B Jenkins
Xochiquetzal J Geiger
P2860
P304
P356
10.1158/1078-0432.CCR-15-0574
P407
P50
P577
2017-05-22T00:00:00Z